Thrombolex is committed to helping provide a new standard of care for the treatment of arterial and venous thromboembolic (A+VTE) conditions. Discover our innovative approach to treatment with the BASHIR™ Family of Endovascular Catheters.
An Elegant, Novel Solution
For Optimal Thrombus Resolution
The Problem
Treating A+VTE safely and effectively while minimizing risk, maximizing clot burden resolution, and producing consistent clinical outcomes is of critical importance.
Our Solution
The unique hybrid mechanism of action of the BASHIR™ family of endovascular catheters allows the use of both mechanical and pharmacological treatment to immediately restore blood flow. This allows for the efficient and safe introduction of thrombolytics to produce positive clinical outcomes.
Product Resources
Product Overview • Product Details
Clinical Resources
Clinical Studies • Instructional Videos
Our Company
Our Mission • Our Leadership
Our Family of Catheters
For restoring blood flow in peripheral and pulmonary vessels
The catheter’s expandable infusion basket allows a controlled and selective infusion of physician-specified fluids.
Available in 7F and 8F sizes.
For restoring blood flow within shorter peripheral and pulmonary vessels
The short basket of the S-B catheter allows navigation and implementation in shorter, more tortuous vessels.
Available in 7F and 8F sizes.
For restoring blood flow in peripheral vessels with extensive thrombus burden
A family of catheters designed to deliver thrombolytics through the expandable infusion basket and along a segment of the catheter shaft.
–
Featured News
Thrombolex Secures $50M Series A Financing to Advance Endovascular Treatment for Pulmonary Embolism and Venous Thrombus
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a...
Interim Data from the RAPID-PE Study Presented at TCT 2025
New Britain, PA - (October 28th, 2025) - Thrombolex, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE, a prospective, multicenter U.S. study evaluating On-The-Table (OTT) pharmaco-mechanical lysis (PML) without any post procedure...
RESCUE-II Study results published in JACC: Advances
New Britain, PA – (June 25, 2025) – Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances....
Rescue II Results
RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis without Post-Procedure Infusion in Treating Acute Pulmonary Embolism NEW BRITAIN, PA (October 28, 2024) — Christian Bichard, MD presented the results of the RESCUE-II Trial during...
RAPID-PE Study News
Thrombolex Announces the First Two Patients enrolled in the RAPID-PE Clinical Study evaluating an Advanced On-The-Table Protocol for the Treatment of Pulmonary Embolism NEW BRITAIN, PA (October 23, 2024) — Thrombolex, Inc. announced the enrollment of the first two...
Thrombolex and Aidoc Announce Strategic Partnership to Advance Breakthrough Pulmonary Embolism Treatment
Proactive collaboration leverages Aidoc's AI technology to accelerate RAPID-PE clinical trial enrollment for Thrombolex's "single session" treatment protocol. NEW BRITAIN, PA, July 30, 2024 – Thrombolex, Inc., an innovator in the development of advanced interventional...
Thrombolex will be attending the Society of Interventional Radiology Annual Scientific Meeting. We look forward to connecting with the interventional radiology community and continuing conversations around targeted PE treatment and procedural approaches that support precision and clinical confidence in patient care.
Thrombolex.com #thrombolex #SIR2026 ... See MoreSee Less
0 CommentsComment on Facebook
Happy Easter from Thrombolex.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
Thrombolex will be attending the Society of Interventional Radiology (SIR) Annual Scientific Meeting coming next month.
We look forward to connecting with the Interventional Radiology community and continuing discussions around targeted PE therapy and procedural approaches that support precision and clinical confidence in patient care.
Thrombolex.com #thrombolex #SIR2026 ... See MoreSee Less
0 CommentsComment on Facebook
Thrombolex has closed a $50M Series A financing led by OrbiMed, with continued support from existing investors.
This milestone strengthens our ability to support clinicians treating pulmonary embolism and artrerial/venous thrombus with approaches that combine mechanical clot engagement and targeted thrombolytic delivery.
The investment will support:
→ Expanded commercial reach to more hospitals and care teams
→ Continued clinical programs, including further evidence generation
→ Organizational growth to support long-term scale
President and CEO Mike Cerminaro highlights the company’s appreciation for its clinical partners, whose insights and feedback continue to guide advances in endovascular treatment.
Learn more in the full announcement: thrombolex.com/thrombolex-secures-50m-series-a-financing-to-advance-endovascular-treatment-for-pu... ... See MoreSee Less
0 CommentsComment on Facebook
The BASHIR™ Plus Endovascular Device is designed for targeted thrombolytic delivery in peripheral vessels. The expandable infusion basket and variable distal-shaft infusion lengths provide procedural flexibility and controlled delivery to support safe and efficient treatment of venous thrombus.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
Combining mechanical fragmentation and targeted lytic delivery, the BASHIR™ Plus Endovascular Device elevates treatment of venous thrombus while giving clinicians clinical confidence.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook